{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:41:14Z","timestamp":1707525674512},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"DOI":"10.7759\/cureus.50957","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T17:06:09Z","timestamp":1703264769000},"source":"Crossref","is-referenced-by-count":0,"title":["A Straining Heart: Transthyretin Amyloidosis as a Cause of Heart Failure"],"prefix":"10.7759","author":[{"given":"Joana","family":"Tender-Vieira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudemira","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Matias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge S","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar E","year":"2021","unstructured":"Muchtar E, Dispenzieri A, Magen H, et al.. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021, 289:268-92. 10.1111\/joim.13169","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson MD","year":"2018","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, et al.. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2018, 25:215-19. 10.1080\/13506129.2018.1549825","journal-title":"Amyloid"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf MU","year":"2023","unstructured":"Rauf MU, Hawkins PN, Cappelli F, et al.. Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. Eur Heart J. 2023, 44:2187-98. 10.1093\/eurheartj\/ehad139","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz MA","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, et al.. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015, 66:2451-66. 10.1016\/j.jacc.2015.09.075","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima Y","year":"2011","unstructured":"Sekijima Y, Uchiyama S, Tojo K, et al.. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011, 42:1785-91. 10.1016\/j.humpath.2011.03.004","journal-title":"Hum Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021, 42:1554-68. 10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: Evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-e22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione V","year":"2021","unstructured":"Castiglione V, Franzini M, Aimo A, et al.. Use of biomarkers to diagnose and manage cardiac amyloidosis. Eur J Heart Fail. 2021, 23:217-30. 10.1002\/ejhf.2113","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight DS","year":"2019","unstructured":"Knight DS, Zumbo G, Barcella W, et al.. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019, 12:823-33. 10.1016\/j.jcmg.2018.02.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.009025","article-title":"Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment","volume":"14","author":"Patel RK","year":"2021","unstructured":"Patel RK, Fontana M, Ruberg FL. Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment. Circ Cardiovasc Imaging. 2021, 14:e009025. 10.1161\/CIRCIMAGING.121.009025","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/212269-a-straining-heart-transthyretin-amyloidosis-as-a-cause-of-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:14Z","timestamp":1707509534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/212269-a-straining-heart-transthyretin-amyloidosis-as-a-cause-of-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.50957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}